Exact Sciences Corporation (EXAS) News

Exact Sciences Corporation (EXAS)

Today's Latest Price: $150.00 USD

1.93 (1.30%)

Updated Jan 22 4:00pm

Add EXAS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

StocksNews Articles for EXAS

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest EXAS News From Around the Web

Below are the latest news stories about Exact Sciences Corp that investors may wish to consider to help them evaluate EXAS as an investment opportunity.

Exact Sciences: Patching The Acquisitions Together

The current cancer treatments lack efficiency, and late diagnostics make everything harder. As a matter of fact, experts have been telling us for a long time that early detection is fundamental to have a significant increase in survival rates. The holy grail for early cancer detections could be a blood...

Nelson Alves on Seeking Alpha | January 21, 2021

Cologuard accurately screens younger individuals for colorectal cancer

The U.S. Preventive Services Task Force (USPSTF) appears on the verge of expanding colorectal cancer screening to individuals ages 45 to 49, based on its latest draft recommendations. If it does, Exact Sciences Corp. is ready. A study in Cancer Prevention Research demonstrated that the Madison, Wis.-based company's Cologuard multitarget stool DNA test had better than 95% specificity in individuals with nonadvanced precancerous lesions or negative findings on colonoscopy.

BioWorld | January 15, 2021

Exact Sciences' colorectal cancer screening test demonstrates low false-positive rate for screening, study shows

Exact Sciences ([[EXAS]] +2.7%) has announced data published in Cancer Prevention Research, a Journal of the American Association for Cancer Research, from a study in 816 eligible participants that showed that among average-risk adults between the ages of 45 and 49, Cologuard demonstrated test specificity of 95.2% in participants with...

Seeking Alpha | January 12, 2021

New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard®

Exact Sciences Corp. (Nasdaq: EXAS) announced data published today in Cancer Prevention Research, a Journal of the American Association for Cancer Research, that expands on foundational clinical study findings to include a key younger population. Study results show that among average-risk adults between the ages of 45 and 49 Cologuard® (mt-sD­­­­NA) demonstrated test specificity of 95.2% in participants with non-advanced precancerous lesions or negative findings at colonoscopy and 96.3% in only those with negative colonoscopy findings. These analyses support potential risk mitigation and cost prevention due to unnecessary diagnostic procedures when using Cologuard as a colorectal cancer screening tool in this younger population. ­­­­­

Yahoo | January 12, 2021

Exact Sciences Scores Relative Strength Rating Upgrade; Hits Key Threshold

Exact Sciences saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 75 to 85. As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength. Exact Sciences is now considered extended and out of buy range after clearing a 139.36 buy point in a second-stage cup with handle.

Yahoo | January 12, 2021

Exact Sciences (EXAS) Soars: Stock Adds 9.8% in Session

Exact Sciences (EXAS) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Yahoo | January 12, 2021

Why Exact Sciences Stock Is Soaring Today

Shares of Exact Sciences (NASDAQ: EXAS) were soaring 12% as of 10:49 a.m. EST on Monday. With such an impressive gain today, it's not surprising that Exact Sciences' preliminary results looked really good. The company expects to post fourth-quarter revenue between $464.5 million and $467.5 million.

Yahoo | January 11, 2021

Exact Sciences Announces Preliminary Fourth Quarter 2020 Results

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $464.5 million and $467.5 million for the fourth quarter ended Dec. 31, 2020.

Yahoo | January 11, 2021

Why The Covid Pandemic Will Be A Boon For These Health Care Stocks

The coronavirus pandemic will continue to captivate the world in 2021. But it could also provide a boon for some health care stocks working in telemedicine, remote monitoring and testing.

Yahoo | January 8, 2021

Exact Sciences Expects To Beat 4Q Revenue Estimates; Street is Bullish

Exact Sciences provided preliminary guidance for its fourth quarter performance as per which, the company expects to exceed consensus revenue estimates. In an SEC filing, Exact Sciences (EXAS) stated that it expects its 4Q overall revenue to beat the FactSet consensus estimate of $427 million. The company also anticipates its screening revenue and precision oncology revenue to top FactSet’s consensus estimates of $230 million and $104 million, respectively. Additionally, it estimates that COVID-19 testing revenue will come in ahead of FactSet’s $92 million consensus forecast. The company disclosed that it has not yet completed the preparation of its financial statements for 4Q or the full year.

Sirisha Bhogaraju on TipRanks | January 6, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5738 seconds.